Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.

作者信息

Choi Su-Mi, Lee Dong-Gun, Choi Jung-Hyun, Yoo Jin-Hong, Kim Yoo-Jin, Park Sun Hee, Min Chang-Ki, Lee Seok, Kim Hee-Je, Kim Dong-Wook, Lee Jong-Wook, Min Woo-Sung, Shin Wan-Shik, Kim Chun-Choo

出版信息

Int J Hematol. 2006 Apr;83(3):277-8. doi: 10.1007/BF02985486.

DOI:10.1007/BF02985486

PMID:16720564

Abstract

摘要

相似文献

Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.

Int J Hematol. 2006 Apr;83(3):277-8. doi: 10.1007/BF02985486.

Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.

Int J Hematol. 2005 Jan;81(1):69-74. doi: 10.1532/ijh97.a30402.

Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience.

Transplantation. 2011 Aug 27;92(4):e17-20. doi: 10.1097/TP.0b013e318224f263.

No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation.

Transpl Infect Dis. 2018 Feb;20(1). doi: 10.1111/tid.12822. Epub 2017 Dec 27.

Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation.

Int J Hematol. 2005 Jun;81(5):439-40. doi: 10.1532/ijh97.05036.

Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain.

J Clin Microbiol. 2015 Aug;53(8):2741-4. doi: 10.1128/JCM.01057-15. Epub 2015 Jun 10.

Risk factors for progression from cytomegalovirus viremia to cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation.

Biol Blood Marrow Transplant. 2012 Jun;18(6):881-6. doi: 10.1016/j.bbmt.2011.10.037. Epub 2011 Nov 4.

Cytomegalovirus infection in pediatric allogenic hematopoietic stem cell transplantation. A single center experience.

Pediatr Hematol Oncol. 2014 Nov;31(8):743-53. doi: 10.3109/08880018.2013.859188. Epub 2013 Dec 5.

Preemptive therapy for cytomegalovirus disease in allogeneic stem cell transplant recipients.

Transplant Proc. 2008 Nov;40(9):3102-3. doi: 10.1016/j.transproceed.2008.08.089.

Chimerism induction and delayed onset of cytomegalovirus (CMV) infection after allogeneic reduced-intensity stem cell transplantation (RIST).

Blood. 2002 Oct 1;100(7):2674-5; author reply 2675-6. doi: 10.1182/blood-2002-04-1175.

本文引用的文献

Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation.

Int J Hematol. 2005 Jun;81(5):439-40. doi: 10.1532/ijh97.05036.

High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation.

Bone Marrow Transplant. 2005 Nov;36(9):813-9. doi: 10.1038/sj.bmt.1705134.

Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.

Int J Hematol. 2005 Jan;81(1):69-74. doi: 10.1532/ijh97.a30402.

High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay.

J Clin Microbiol. 2002 Jun;40(6):2285-7. doi: 10.1128/JCM.40.6.2285-2287.2002.

Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.

Bone Marrow Transplant. 2001 Feb;27(4):437-44. doi: 10.1038/sj.bmt.1702805.

Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.

Bone Marrow Transplant. 2000 Apr;25(7):765-9. doi: 10.1038/sj.bmt.1702227.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验